2seventy bio Inc (TSVT)
4.255
-0.04
(-0.82%)
USD |
NASDAQ |
Apr 26, 16:00
4.255
0.00 (0.00%)
After-Hours: 20:00
2seventy bio Research and Development Expense (TTM): 230.76M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 230.76M |
| September 30, 2023 | 239.68M |
| June 30, 2023 | 246.52M |
| March 31, 2023 | 251.10M |
| December 31, 2022 | 248.74M |
| September 30, 2022 | 238.81M |
| Date | Value |
|---|---|
| June 30, 2022 | 241.79M |
| March 31, 2022 | 240.92M |
| December 31, 2021 | 252.62M |
| September 30, 2021 | 271.28M |
| June 30, 2021 | 282.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
230.76M
Minimum
Dec 2023
282.40M
Maximum
Jun 2021
249.51M
Average
246.52M
Median
Jun 2023
Research and Development Expense (TTM) Benchmarks
| Bristol-Myers Squibb Co | 9.673B |
| Johnson & Johnson | 15.30B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Macrogenics Inc | 166.58M |
| Akebia Therapeutics Inc | 63.08M |